Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations. Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib Program: Oral and Poster Abstracts | Monday, December 3, 2018: 11:45 AM Type: Oral Session: 642. CLL: Therapy, excluding Transplantation: Advances in CLL Using Novel Combination Therapy Introduction: We previously reported a prognostic scoring system in CLL using pre-treatment factors in patients treated with ibrutinib [Ahn et al, 2016 ASH Annual Meeting]. Here we present long-term follow-up results and validation of the prognostic models in a large independent cohort of patients. We also determine the incidence […]
Why not Stay in Touch…?
- Time Matters on Health Tests [TAT-NGS]
- Myelodysplastic Syndrome (MDS)
- Genomic Testing Cooperative Receives Medicare (Palmetto GBA) Coverage for two NGS Hematology Molecular Profiling Tests Including Liquid Biopsy for Hematologic Neoplasms
- Comprehensive PIK3CA Mutation Analysis
- The FDA has Approved Drugs for FGFR Abnormalities
acute myeloid leukemia Adult AI AML apoptosis B-Cell Lymphoma beta 2-Microglobulin Biological Biological Processes Biomarkers bone marrow BTK Case Study chemotherapy Clinically relevant CLL Congress Diseases DNA profiling enzyme inhibitors genetic profiling genomic testing gtc hematology ibrutinib Janus Kinase 2 Ki-67 Antigen leukemia liquid biopsy Lymphoid Malignancies Myeloid Malignancies ngs Non-Biological PLCγ2 press release Receptors resistance RNA sequencing signal transduction Study Population Technology and Procedures Therapies Thrombopoietin TKI Young Adult